CANSINOBIO

The stock edged up 0.43% to HKD 23.28, balancing international expansion momentum against Q1 earnings deterioration; shares climbed to an intraday high of HKD 23.54 in morning trading before retreating in the afternoon. Recent catalysts remain constructive: a letter of intent signed with Pakistan's AGP to explore PCV13i vaccine opportunities, regulatory acceptance of Menhycia label expansion to age 17, and MCV4 approval in Argentina underscore the company's advancing international presence. However, Q1 results reveal significant earnings pressure—net loss widened to HKD 45.83 million with net margin contracted to -21.24%, reversing Q4's profit recovery. Share price positioning reflects this tension: down 33.41% year-to-date, it has declined 58.83% from the 52-week high of HKD 56.55. UBS maintains a Buy rating with a target price of HKD 52.4, signaling confidence in the long-term vaccine pipeline, though near-term profit recovery will be critical to market sentiment.

CanSino Biologics declined approximately 2% to close at HK$23.18, primarily dragged by disappointing Q1 2026 earnings. Although Q1 revenue reached HK$215.73M, up 46.86% year-over-year, the company swung to a net loss of HK$45.83M, representing a 270.65% year-over-year decline and a net margin of -21.24%. Intraday weakness occurred early as the stock opened at HK$23.50 and retreated to a session low of HK$22.98 at 11:22 AM Beijing time before recovering in the afternoon session to HK$23.30 before settling at HK$23.18. From a technical perspective, the stock remains below its 20-day moving average of HK$23.67 and is down 33.7% year-to-date, trading 59.01% below its 52-week high of HK$56.55 reached on September 8, 2025. Recent positive catalysts including Menhycia label expansion approval to age 17, MCV4 registration approval in Argentina, and a partnership with Pakistan's AGP to explore PCV13i vaccine opportunities have not offset near-term investor concerns about profitability deterioration. UBS maintains a Buy rating with a HK$52.4 price target, implying 127% upside from current levels and reflecting institutional confidence in medium-term prospects that diverges from prevailing market pricing.

CanSino closed flat today, having plummeted 58.62% from its September 2025 peak of HK$56.55 and fallen 33.07% year-to-date, primarily due to Q1 2026's profit deterioration—despite revenue climbing 46.86% to HK$215.7 million, the company swung to a net loss of HK$45.8 million with net margin collapsing to -21.24%. UBS cut its target price to HK$52.4 in response. On the product front, the vaccine pipeline continues advancing: Menhycia label expansion to age 17 was accepted by China's regulator, MCV4 received approval in Argentina, and PCV13i collaboration launched with Pakistan's AGP. However, with a negative PE and PB of just 1.04, recovery depends on demonstrating earnings stabilization.

CanSino Biologics (6185.HK) closed lower today, retreating from the morning high of HKD23.74 to HKD23.40 amid profit-taking. Recent headlines—a PCV13i vaccine cooperation LOI with Pakistan's AGP, Menhycia label expansion in China, and MCV4 approval in Argentina—fail to offset earnings concerns. Q1 results showed a net loss of HKD45.83M and EPS of HKD-0.1814, despite 46.86% revenue growth to HKD215.73M. UBS cut its price target to HKD52.4, signaling skepticism on near-term recovery. Year-to-date, the stock is down 33.07%, having fallen 58.62% from the 52-week high of HKD56.55, now trading below the 20-day moving average at HKD23.549, reflecting persistent doubts on profitability improvement.

CanSino Biologics closed flat at HK$23.38, down 0.17%, amid mixed signals from deteriorating Q1 earnings and ongoing international vaccine expansion. The morning session opened at HK$23.78 but retreated to HK$23.46, while the afternoon session recovered slightly to the closing price. The stock has plunged 58% from its 52-week high of HK$56.55 and is down 33% year-to-date, while rebounding 21.64% from its 52-week low of HK$19.22. Q1 2026 showed significant headwinds: the company swung to a net loss of HK$45.83 million (down 270.65% YoY), despite revenue growth of 46.86% YoY to HK$215.73 million, with net margin turning sharply negative to -21.24%, signaling cost pressures. On the positive side, recent developments include signing a PCV13i vaccine accord with Pakistan's AGP, MCV4 regulatory approval in Argentina, and Menhycia label expansion to age 17 in China. However, UBS maintained its buy rating but cut its target price to HK$52.4, suggesting elevated prior expectations; these international initiatives remain pre-revenue, and the earnings deterioration keeps market sentiment cautious.